Skip to main content
SpringerLink
Log in

Organ-Specific Gadolinium-Based Contrast Media

  • Chapter
Contrast Media

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 2907 Accesses

Abstract

Organ-specific contrast agents were developed after conventional extracellular gadolinium chelates and there are fewer data about their safety. They belong to different classes of agent and therefore exhibit different physicochemical properties, modes of action, and metabolic pathways. Currently, agents for both hepatobiliary imaging and blood pool imaging are available commercially. Based on laboratory data, all these agents are considered to be in the ‘intermediate risk’ category for inducing NSF. NSF has not been reported after any of these agents, but clinical experience is extremely limited for two of them.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Bellin MF, Zaim S, Auberton E et al (1994) Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 193:657–663

    CAS  PubMed  Google Scholar 

  • Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688–2698

    Article  CAS  PubMed  Google Scholar 

  • Bluemke AD, Sahani D, Amendola M et al (2005) Efficacy and safety of MR imaging with liver specific contrast agent: US multicenter phase III study. Radiology 237:89–98

    Article  PubMed  Google Scholar 

  • Bollow M, Taupitz M, Hamm B et al (1997) Gadolinium-ethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 7:126–132

    Article  CAS  PubMed  Google Scholar 

  • Bosch E, Kreitner KF, Peirano MF et al (2008) Safety and efficacy of gadofosveset-enhanced MR angiography for evaluation of pedal arterial disease: multicenter comparative phase III study. Am J Roentgenol 190:179–186

    Article  Google Scholar 

  • Breuer J, Balzer T, Shamsi K et al (2003) Clinical experience from phase II and phase III studies for Gd-EOB-DTPA: a new liver specific MR contrast agent. Eur Radiol 13(Suppl 2):S109

    Google Scholar 

  • Brismar TB, Kartalis N, Kylander C, Albiin N (2012) MRI of colorectal cancer liver metastases: comparison of orally administered manganese with intravenously administered gadobenate dimeglumine. Eur Radiol 22:633–641

    Article  PubMed  PubMed Central  Google Scholar 

  • Caravan P, Comuzzi C, Crooks W et al (2001) Thermodynamic stability and kinetic inertness of MS-325, a new blood pool agent for magnetic resonance imaging. Inorg Chem 40:2170–2176

    Article  CAS  PubMed  Google Scholar 

  • Caudana R, Morana G, Pirovano GP et al (1996) Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)–preliminary results of phase II clinical application. Radiology 199:513–520

    CAS  PubMed  Google Scholar 

  • Cavagna FM, Maggioni F, Castelli PM et al (1997) Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 32:780–796

    Article  CAS  PubMed  Google Scholar 

  • Chrysochou C, Power A, Shurrab AE et al (2010) Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 5:484–489

    Article  PubMed  Google Scholar 

  • Davenport MS, Viglianti BL, Al-Hawary MM et al (2013) Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology 266:452–461

    Google Scholar 

  • Dohr O, Hofmeister R, Treher M, Schweinfurth H (2007) Preclinical safety evaluation of Gd-EOB-DTPA (Primovist). Invest Radiol 42:830–841

    Article  PubMed  Google Scholar 

  • Giovagnoni A, Paci E (1996) Liver III: gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg). Magn Reson Imaging Clin North Am 4:61–72

    CAS  Google Scholar 

  • Goyen M, Edelman M, Perreault P et al (2005) MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 236:825–833

    Article  PubMed  Google Scholar 

  • Grazioli L, Morana G, Caudana R et al (2000) Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathological findings. Invest Radiol 35:25–34

    Article  CAS  PubMed  Google Scholar 

  • Gschwend S, Ebert W, Schultze-Mosgau M, Breuer J (2011) Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Invest Radiol 46:556–566

    Article  CAS  PubMed  Google Scholar 

  • Halavaara J, Breuer J, Ayuso C et al (2006) Liver tumor characterization: comparison between liver-specific Gd-EOB-DTPA-enhanced MRI and biphasic CT: a multicenter trial. J Comput Assist Tomogr 30:345–354

    Article  PubMed  Google Scholar 

  • Hamm B, Staks T, Mühler A et al (1995) Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195:785–792

    CAS  PubMed  Google Scholar 

  • Hamm B, Kirchin M, Pirovano G et al (1999) Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: results of multicenter studies in Europe and the USA. J Comput Assist Tomogr 23(Suppl 1):S53–S60

    Article  PubMed  Google Scholar 

  • Herborn CU, Jäger-Booth I, Lodemann KP et al (2009) Multicenter analysis of tolerance and clinical safety of the extracellular MR contrast agent gadobenate dimeglumine (MultiHance). Rofo 181:652–657

    Article  CAS  PubMed  Google Scholar 

  • Huppertz A, Balzer T, Blakeborough A et al for the European EOB Study Group (2004) Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 230:266–275

    Article  Google Scholar 

  • Ichikawa T, Saito K, Yoshioka N et al (2010) Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease. Invest Radiol 45:133–141

    Article  PubMed  Google Scholar 

  • Iezzi R, Soulez G, Thurnher S et al (2011) Contrast-enhanced MRA of the renal and aorto-iliac-femoral arteries: comparison of gadobenate dimeglumine and gadofosveset trisodium. Eur J Radiol 77:358–368

    Article  PubMed  Google Scholar 

  • Kato N, Yokawa T, Tamura A et al (2002) Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol 37:680–684

    Article  CAS  PubMed  Google Scholar 

  • Kirchin MA, Runge VM (2003) Contrast agents for magnetic resonance imaging: safety update. Top Magn Reson Imaging 14:426–435

    Article  PubMed  Google Scholar 

  • Kirchin MA, Pirovano G, Spinazzi A (1998) Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 33:798–809

    Article  CAS  PubMed  Google Scholar 

  • Kirchin MA, Pirovano G, Venetianer C et al (2001) Safety assessment of gadobenate dimeglumine (MultiHance): extended clinical experience from phase I studies to post-marketing surveillance. J Magn Reson Imaging 14:281–294

    Article  CAS  PubMed  Google Scholar 

  • Kuwatsuru R, Kadoya M, Ohtomo K et al (2001) Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors. Invest Radiol 36:632–641

    Google Scholar 

  • Lin SP, Brown JJ (2007) MR contrast agents: physical and pharmacologic basics. J Magn Reson Imaging 25:884–899

    Article  PubMed  Google Scholar 

  • Manfredi R, Maresca G, Baron RL et al (1998) Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 8:862–867

    Article  Google Scholar 

  • Manfredi R, Maresca G, Baron RL et al. (1999) Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA). J Magn Reson Imaging 9:704–710

    Google Scholar 

  • Martincich L, Faivre-Pierret M, Zechmann CM et al (2011) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT Trial). Radiology 258:396–408

    Article  PubMed  Google Scholar 

  • Nikolaou K, Kramer H, Grosse D et al (2006) High-spatial-resolution multistation MR angiography with parallel imaging and blood pool agent: initial experience. Radiology 241:861–872

    Article  PubMed  Google Scholar 

  • Perreault P, Edelman MA, Baum RA et al (2003) MR angiography with gadofosveset trisodium for peripheral vascular disease phase II trial. Radiology 229:811–820

    Google Scholar 

  • Peterstein J, Spinazzi A, Giovagnoni A et al (2000) Evaluation of the efficacy of gadobenate dimeglumine in magnetic resonance imaging of focal liver lesions: a multicenter phase III clinical study. Radiology 215:727–736

    Article  Google Scholar 

  • Raman SS, Leary C, Bluemke DA et al (United States EOB Study Group) (2010) Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase III clinical trial. J Comput Assist Tomogr 34:163–172

    Article  Google Scholar 

  • Rapp JH, Wolff SD, Quinn JA et al (2005) Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography-multicenter comparative phase III study. Radiology 236:71–78

    Article  PubMed  Google Scholar 

  • Reimer P, Rummeny EJ, Shamsi K et al (1996) Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 199:177–183

    CAS  PubMed  Google Scholar 

  • Reimer P, Schneider G, Schima W (2004) Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14:559–578

    Article  PubMed  Google Scholar 

  • Rosati G, Pirovano G, Spinazzi A (1994) Interim results of phase II clinical testing of gadobenate dimeglumine. Invest Radiol 29:S183–S185

    Article  PubMed  Google Scholar 

  • Schuhmann-Giampieri G, Schmitt-Willich H, Press WR et al (1992) Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology 183:59–64

    CAS  PubMed  Google Scholar 

  • Shamsi K, Yucel EK, Chamberlin P (2006) A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: phase II and phase III clinical trials data. Invest Radiol 41:822–830

    Article  CAS  PubMed  Google Scholar 

  • Shellock FG, Parker JR, Pirovano G et al (2006) Safety characteristics of gadobenate dimeglumine: clinical experience from intra-and interindividual comparison studies with gadopentetate dimeglumine. J Magn Reson Imaging 24:1378–1385

    Article  PubMed  Google Scholar 

  • Schneider G, Pasowicz M, Vymazal J et al (2010) Gadobenate dimeglumine and gadofosveset trisodium for MR angiography of the renal arteries: Multicenter intraindividual crossover comparison. AJR Am J Roentgenol 195:476–485

    Article  PubMed  Google Scholar 

  • Schneider G, Schürholz H, Kirchin MA et al (2013) Safety and adverse effects during 24 hours after contrast-enhanced MRI with gadobenate dimeglumine (MultiHance®) in children. Pediatr Radiol 43:202–211

    Article  PubMed  Google Scholar 

  • Spinazzi A, Lorusso V, Pirovano G et al (1999) Safety, tolerance, biodistribution and MR imaging enhancement of the liver with Gd-BOPTA: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 6:282–291

    Article  CAS  PubMed  Google Scholar 

  • Steger-Hartmann T, Graham PB, Müller S, Schweinfurth H (2006) Preclinical safety assessment of Vasovist (gadofosveset trisodium), a new paramagnetic resonance imaging contrast agent for angiography. Invest Radiol 41:449–459

    Google Scholar 

  • Stenver DI (2008) Pharmacovigilance: What to do if you see an adverse reaction and the consequences. Eur J Radiol 66:184–186

    Article  PubMed  Google Scholar 

  • Stern W, Schick F, Kopp AF et al (2000) Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 41:255–262

    Article  CAS  PubMed  Google Scholar 

  • Vogl TJ, Stupavsky A, Pegios W et al (1997) Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 205:721–728

    CAS  PubMed  Google Scholar 

  • Weinmann HJ, Schuhmann-Gampieri G, Schmitt-Willich H et al (1992) A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 22:233–237

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Radiologie Générale Adultes, Hôpital de Bicêtre, Secteur Paul Broca, 78 rue du Général Leclerc, 94275, Le Kremlin-Bicêtre Cedex, France

    Marie-France Bellin

  2. Department of Radiology, Skåne University Hospital, Inga-Marie Nilssons Gata 49, 205 02, Malmö, Sweden

    Peter Leander

Authors
  1. Marie-France Bellin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Leander
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marie-France Bellin .

Editor information

Editors and Affiliations

  1. Copenhagen University Hospital, Herlev, Denmark

    Henrik S. Thomsen

  2. Diagnostic Radiology Dept., St. Bartholomews Hospital, London, United Kingdom

    Judith A. W. Webb

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Bellin, MF., Leander, P. (2014). Organ-Specific Gadolinium-Based Contrast Media. In: Thomsen, H., Webb, J. (eds) Contrast Media. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2013_898

Download citation

  • DOI: https://doi.org/10.1007/174_2013_898

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-36723-6

  • Online ISBN: 978-3-642-36724-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation